Basis of Presentation (Tables)

9 Months Ended

Sep. 30, 2022

Basis of Presentation

Impact of the restatement on the unaudited consolidated balance sheets

	September 30, 2021 (Unaudited)
	As Previously
Balance Sheet	Reported		Adjustment		As Restated
Additional paid-in capital	$	337,125,126	$	5,519,504	$	342,644,630
Accumulated deficit	$	(186,059,869)	$	(5,519,504)	$	(191,579,373)

Impact of the restatement on consolidated statements of operations

	For the Three Months Ended September 30, 2021 (Unaudited)						For the Nine Months Ended September 30, 2021 (Unaudited)
	As Previously						As Previously
Condensed Statement of Operations	Reported		Adjustment		As Restated		Reported		Adjustment		As Restated
Total Sales	$	3,018,774	$	—	$	3,018,774	$	9,850,702	$	—	$	9,850,702
Total Cost of Sales		2,435,437		—		2,435,437		7,608,401		—		7,608,401
Gross Profit		583,337		—		583,337		2,242,301		—		2,242,301
Operating Expenses:
Research and Development		3,270,255		126,863		3,397,118		8,050,915		275,516		8,326,431
Selling and Marketing		1,589,582		63,431		1,653,013		4,167,874		137,758		4,305,632
General and Administrative		3,112,059		2,351,188		5,463,247		11,565,816		5,106,230		16,672,046
Depreciation and Amortization		434,277		—		434,277		1,453,367		—		1,453,367
Loss on Fixed Asset Disposal		—		—		—		83,908		—		83,908
Impairment of Patents and Trademarks		7,544		—		7,544		66,040		—		66,040
Total Operating Expenses		8,413,717		2,541,482		10,955,199		25,387,920		5,519,504		30,907,424
Loss From Operations		(7,830,380)		(2,541,482)		(10,371,862)		(23,145,619)		(5,519,504)		(28,665,123)
Total Other Expense, Net		(115,686)		—		(115,686)		(219,267)		—		(219,267)
Net Loss	$	(7,946,066)	$	(2,541,482)	$	(10,487,548)	$	(23,364,886)	$	(5,519,504)	$	(28,884,390)
Basic and Diluted Loss per Common Share	$	(0.13)	$	(0.04)	$	(0.17)	$	(0.39)	$	(0.10)	$	(0.48)

Impact of the restatement on statement of stockholders' equity

	For the Nine Months Ended September 30, 2021 (Unaudited)
	As Previously
Condensed Statement of Changes in Stockholders' Equity	Reported		Adjustment		As Restated
Stock-Based Compensation Expense	$	8,858,814	$	5,519,504	$	14,378,318
Additional Paid-In Capital		337,125,126		5,519,504		342,644,630
Net Loss		(23,364,886)		(5,519,504)		(28,884,390)
Accumulated Deficit	$	(186,059,869)	$	(5,519,504)	$	(191,579,373)

Impact of the restatement on consolidated statements of cash flow

	For the Nine Months Ended September 30, 2021 (Unaudited)
	As Previously
Condensed Statement of Cash Flows	Reported		Adjustment		As Restated
Net Loss	$	(23,364,886)	$	(5,519,504)	$	(28,884,390)
Stock-Based Compensation		7,311,278		5,519,504		12,830,782
Net Cash Flows Used in Operating Activities	$	(18,909,428)	$	—	$	(18,909,428)

Reclassification of prior year presentation

	For the Three Months Ended September 30, 2021 (Unaudited)						For the Nine Months Ended September 30, 2021 (Unaudited)
Condensed Statement of Operations	As Restated		Reclassification		Revised		As Restated		Reclassification		Revised
Total Sales	$	3,018,774	$	—	$	3,018,774	$	9,850,702	$	—	$	9,850,702
Total Cost of Sales		2,435,437		187,375		2,622,812		7,608,401		722,332		8,330,733
Gross Profit		583,337		(187,375)		395,962		2,242,301		(722,332)		1,519,969
Operating Expenses:				—
Research and Development		3,397,118		—		3,397,118		8,326,431		—		8,326,431
Selling and Marketing		1,653,013		—		1,653,013		4,305,632		—		4,305,632
General and Administrative		5,463,247		—		5,463,247		16,672,046		—		16,672,046
Depreciation and Amortization		434,277		(187,375)		246,902		1,453,367		(722,332)		731,035
Loss on Fixed Asset Disposal		—		—		—		83,908		—		83,908
Impairment of Patents and Trademarks		7,544		—		7,544		66,040		—		66,040
Total Operating Expenses		10,955,199		(187,375)		10,767,824		30,907,424		(722,332)		30,185,092
Loss From Operations		(10,371,862)		—		(10,371,862)		(28,665,123)		—		(28,665,123)
Total Other Expense, Net		(115,686)		—		(115,686)		(219,267)		—		(219,267)
Net Loss	$	(10,487,548)	$	—	$	(10,487,548)	$	(28,884,390)	$	—	$	(28,884,390)